Avalo Therapeutics, Inc.·4

May 24, 4:15 PM ET

Caissa Capital Management ltd. 4

4 · Avalo Therapeutics, Inc. · Filed May 24, 2023

Insider Transaction Report

Form 4
Period: 2023-05-24
Transactions
  • Purchase

    Common Stock

    2023-05-24$2.96/sh+5,519$16,3481,382,700 total(indirect: See Footnote (1))
  • Purchase

    Common Stock

    2023-05-24$3.01/sh+3,481$10,4681,377,181 total(indirect: See Footnote (1))
Holdings
  • Common Stock

    182,300
Footnotes (4)
  • [F1]Shares held by Caissa Capital Management Ltd, a British Virgin Islands company controlled by Mr. Golestaneh.
  • [F2]The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.0 to $3.01, inclusive.
  • [F3]The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.92 to $3.03, inclusive.
  • [F4]These shares are directly owned by Mr. Golestaneh in his personal capacity.

Documents

1 file
  • 4
    primary_doc.xmlPrimary

    PRIMARY DOCUMENT